Clinicopathological and molecular differences between stage IV screen-detected and interval colorectal cancers in the Flemish screening program

Introduction Interval cancer (IC) is an important quality indicator in colorectal cancer (CRC) screening. Previously, we found that fecal immunochemical test (FIT) ICs are more common in women, older age, right-sided tumors, and advanced stage. Here, we extended our existing stage IV patient cohort with clinicopathological and molecular characteristics, to identify factors associated with FIT-IC. Methods Logistic regression models were fit to identify variables associated with the odds of having a stage IV FIT-IC. Multivariate models were corrected for gender, age, and location. Results A tota... Mehr ...

Verfasser: Neefs, Isabelle
Tran, Thuy Ngan
Ferrari, Allegra
Janssens, Sharon
Van Herck, Koen
Op de Beeck, Ken
Van Camp, Guy
Peeters, Marc
Fransen, Erik
Hoeck, Sarah
Van Hal, Guido
Dokumenttyp: Artikel
Erscheinungsdatum: 2024
Reihe/Periodikum: Frontiers in Oncology ; volume 14 ; ISSN 2234-943X
Verlag/Hrsg.: Frontiers Media SA
Sprache: unknown
Permalink: https://search.fid-benelux.de/Record/base-29060969
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : http://dx.doi.org/10.3389/fonc.2024.1409196

Introduction Interval cancer (IC) is an important quality indicator in colorectal cancer (CRC) screening. Previously, we found that fecal immunochemical test (FIT) ICs are more common in women, older age, right-sided tumors, and advanced stage. Here, we extended our existing stage IV patient cohort with clinicopathological and molecular characteristics, to identify factors associated with FIT-IC. Methods Logistic regression models were fit to identify variables associated with the odds of having a stage IV FIT-IC. Multivariate models were corrected for gender, age, and location. Results A total of 292 screen-detected (SD) CRCs and 215 FIT-IC CRCs were included. FIT-IC CRC had 5 fold higher odds to be a neuroendocrine (NET) tumor and 2.5 fold higher odds to have lymphovascular invasion. Interestingly, some variables lost significance upon accounting for location. Thus, tumor location is a critical covariate that should always be included when evaluating factors related to FIT-IC. Conclusions We identified NETs and lymphovascular invasion as factors associated with increased odds of having a stage IV FIT-IC. Moreover, we highlight the importance of tumor location as a covariate in evaluating FIT-IC related factors. More research across all stages is needed to clarify how these insights might help to optimize the Flemish CRC screening program.